Health Catalyst Acquires Oncology-Focused Health Technology Company Carevive
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff pulls Wall Street to two-week lows as oil and yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- U.S. EV market shows signs of bottoming out: Bernstein
Citi Reiterates Buy Rating on Health Catalyst Inc. (HCAT)
June 6, 2024 10:32 AM EDTCiti analyst Daniel Grosslight reiterated a Buy rating and $9.00 price target on Health Catalyst Inc. (NASDAQ: HCAT).
The analyst comments "We caught up with HCAT after the company announced its acquisition of Carevive, an oncology-focused health tech company (LINK). Carevive serves both Oncology Practices and Life... More
